Clinical Trial Update: SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating SR-Exenatide (PT320) for efficacy and safety in early Parkinson's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• SR-Exenatide (PT320) (Exenatide derivative PT320)

Snippet

Sponsor: Peptron, Inc. | Conditions: Early Parkinson's Disease | Phase 2 | Status: UNKNOWN